Filing Details
- Accession Number:
- 0001203311-19-000047
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-09-27 18:12:14
- Reporting Period:
- 2019-09-25
- Accepted Time:
- 2019-09-27 18:12:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seattle Genetics Inc | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1741836 | D Roger Dansey | 21823 30Th Drive Se Bothell WA 98021 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-09-25 | 2,510 | $73.72 | 103,636 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-09-25 | 490 | $74.24 | 103,146 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $73.22 to $74.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $74.23 to $74.28. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Billionaire Hedge Funds
